Molecular Response to Imatinib and Its Correlation with mRNA Expression Levels of Imatinib Influx Transporter (OCT1) in Indian Chronic Myeloid Leukemia Patients

BACKGROUND AND OBJECTIVES: Imatinib mesylate is approved for the treatment of Chronic Myeloid Leukemia (CML). About 20% of patients with CML do not respond to treatment with Imatinib either initially or because of acquired resistance. In addition to mutated BCR-ABL1 kinase, the organic cation transp...

Descripción completa

Detalles Bibliográficos
Autores principales: Chhikara, S, Sazawal, S, Seth, T, Chaubey, R, Singh, K, Sharma, R, Mishra, P, Mahapatra, M, Saxena, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697457/
https://www.ncbi.nlm.nih.gov/pubmed/28843219
http://dx.doi.org/10.22034/APJCP.2017.18.8.2043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697457/
https://www.ncbi.nlm.nih.gov/pubmed/28843219
http://dx.doi.org/10.22034/APJCP.2017.18.8.2043

Ejemplares similares